Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims

Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo

India gets first real-time GLP-1 therapy monitoring platform

As Tracky launches integrated health solution

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories

Cambrex advances $120M US API expansion with Charles City Engineering milestone

The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

New diabetes drug UBT251 shows strong phase 2 results in China